Cargando…

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts

We quantified concentrations of three isoforms of the endolysosomal lipid, bis(monoacylglycerol) phosphate (BMP) in the urine of deeply phenotyped cohorts in the Parkinson’s Progression Markers Initiative: LRRK2 G2019S PD (N = 134) and non-manifesting carriers (NMC) (G2019S+ NMC; N = 182), LRRK2 R14...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merchant, Kalpana M., Simuni, Tanya, Fedler, Janel, Caspell-Garcia, Chelsea, Brumm, Michael, Nudelman, Kelly N. H., Tengstrandt, Elizabeth, Hsieh, Frank, Alcalay, Roy N., Coffey, Christopher, Chahine, Lana, Foroud, Tatiana, Singleton, Andrew, Weintraub, Daniel, Hutten, Samantha, Sherer, Todd, Mollenhauer, Brit, Siderowf, Andrew, Tanner, Caroline, Marek, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974978/ https://www.ncbi.nlm.nih.gov/pubmed/36854767 http://dx.doi.org/10.1038/s41531-023-00468-2

Ejemplares similares

Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2022)

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
por: Marek, Kenneth, et al.
Publicado: (2018)

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson’s disease enrolled in PPMI
por: Huh, Young Eun, et al.
Publicado: (2021)

Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
por: Brumm, Michael C., et al.
Publicado: (2023)

Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures
por: Chahine, Lana M., et al.
Publicado: (2019)

Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder
por: Chahine, Lana M., et al.
Publicado: (2020)

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study
por: Weintraub, Daniel, et al.
Publicado: (2023)

Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression
por: Ortega, Roberto A., et al.
Publicado: (2021)

Proposal for a Biologic Staging System of Parkinson’s Disease
por: Chahine, Lana M., et al.
Publicado: (2023)

Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease
por: Bartl, Michael, et al.
Publicado: (2021)

Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers
por: Thaler, Avner, et al.
Publicado: (2021)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

Genetic Testing for GBA and LRRK2 Mutations: Is it Time for Routine Use?
por: Roopnarain, Karisha, et al.
Publicado: (2023)

Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression
por: Mollenhauer, Brit, et al.
Publicado: (2020)

Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients
por: Alcalay, Roy N., et al.
Publicado: (2020)

Cognition among individuals along a spectrum of increased risk for Parkinson’s disease
por: Chahine, Lana M., et al.
Publicado: (2018)

LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease
por: Pang, Shirley Yin-Yu, et al.
Publicado: (2022)

Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
por: Weintraub, Daniel, et al.
Publicado: (2020)

Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease
por: Thaler, Avner, et al.
Publicado: (2020)

Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers
por: Droby, Amgad, et al.
Publicado: (2022)

Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease
por: Smith, Laura J., et al.
Publicado: (2022)

Lysosomal Pathogenesis of Parkinson’s Disease: Insights From LRRK2 and GBA1 Rodent Models
por: Volta, Mattia
Publicado: (2022)

Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older
por: Brumm, Michael C., et al.
Publicado: (2023)

Novel Variants in LRRK2 and GBA Identified in Latino Parkinson Disease Cohort Enriched for Caribbean Origin
por: Nuytemans, Karen, et al.
Publicado: (2020)

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)
por: Chahine, Lana M., et al.
Publicado: (2018)

Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
por: Kremer, Thomas, et al.
Publicado: (2021)

Precision medicine in Parkinson’s disease patients with LRRK2 and GBA risk variants – Let’s get even more personal
por: von Linstow, Christian U., et al.
Publicado: (2020)

Parkinson’s disease in a patient with GBA and LRRK2 covariants after acute hypoxic insult: a case report
por: Tang, Yuting, et al.
Publicado: (2023)

The Prejudice towards People with Mental Illness (PPMI) scale: structure and validity
por: Kenny, Amanda, et al.
Publicado: (2018)

Predicting miRNA-disease associations based on PPMI and attention network
por: Xie, Xuping, et al.
Publicado: (2023)

In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease
por: Chahine, Lana M., et al.
Publicado: (2020)

An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 Cohorts
por: Padmanabhan, Shalini, et al.
Publicado: (2020)

Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease
por: Surface, Matthew, et al.
Publicado: (2021)

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
por: Eusebi, Paolo, et al.
Publicado: (2018)

Extrastriatal (123)I-FP-CIT SPECT impairment in Parkinson’s disease – the PPMI cohort
por: Nicastro, Nicolas, et al.
Publicado: (2020)

Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort
por: Mihaescu, Alexander S., et al.
Publicado: (2022)

Rare variants in LRRK1 and Parkinson's disease
por: Schulte, Eva C., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8or6vrp71pbifuhmao4pknjrg7